Vertex Pharmaceuticals Incorporated
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000C1S2X2
VRTX
Vertex Pharmaceuticals Incorporated
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Biotechnology
NAME
Vertex Pharmaceuticals Incorporated
ISIN
US92532F1003
TICKER
VRTX
MIC
XNAS
REUTERS
VRTX.OQ
BLOOMBERG
VRTX US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Fr., 28.03.2025
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D) portfolio.
VX-264 Update
Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study, participants received t...
Vertex Pharmaceuticals
Fr., 07.03.2025
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment for peo...
Vertex Pharmaceuticals
Fr., 28.02.2025
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor for the treatment of people with cystic fibrosis (CF) aged 2 years and...
Vertex Pharmaceuticals
Di., 18.02.2025
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences.
Stuart Arbuckle, Executive Vice President and Chief Operating Officer, and David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer will participate in a fireside chat at...
Vertex Pharmaceuticals
Mo., 10.02.2025
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided its full year 2025 financial guidance.
“2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another important year with the landmark JOURNAVX app...
Vertex Pharmaceuticals
Fr., 31.01.2025
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel).
The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guid...
Vertex Pharmaceuticals
Fr., 31.01.2025
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medicine without eviden...
Vertex Pharmaceuticals
Mo., 27.01.2025
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and re...
Vertex Pharmaceuticals
So., 12.01.2025
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled webcast from the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 a.m. ET/7:30 a.m. PT.
“2024 marked another year of excellent progress fo...
Vertex Pharmaceuticals
Fr., 10.01.2025
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a rec...
Vertex Pharmaceuticals
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
